Table 2.
Published studies of risk-reducing salpingo-oophorectomy and cancer risk in BRCA1/2 mutation carriers*
| Study, first author, and year (reference) | Ovarian and/or fallopian tube cancer by mutation status |
Breast cancer by mutation status |
||||
| BRCA1/2 | BRCA1 | BRCA2 | BRCA1/2 | BRCA1 | BRCA2 | |
| Rebbeck et al., 1999 (9) | NA | NA | NA | NA | HR = 0.53 (0.33 to 0.84), N = 122† | NA |
| Kauff et al., 2002 (10) | HR = 0.15 (0.02 to 1.31), N = 170† | NA | NA | HR = 0.32 (0.08 to 1.20), N = 131† | NA | NA |
| Rebbeck et al., 2002 (8) | HR = 0.04 (0.01 to 0.16), N = 551† | NA | NA | HR = 0.47 (0.29 to 0.77), N = 241† | NA | NA |
| Rutter et al., 2003 (17) | OR = 0.29 (0.12 to 0.73), N = 251 | NA | NA | NA | NA | NA |
| Eisen et al., 2005 (15) | NA | NA | NA | OR = 0.46 (0.32 to 0.65), N = 3305 | OR = 0.44 (0.29 to 0.66), N = 2432 | OR = 0.57 (0.28 to 1.15), N = 873 |
| Kramer et al., 2005 (12) | NA | NA | NA | NA | HR = 0.38 (0.15 to 0.97), N = 98 | NA |
| Domchek et al., 2006 (13) | HR = 0.11 (0.03 to 0.47), N = 426† | NA | NA | HR = 0.36 (0.20 to 0.67), N = 426† | NA | NA |
| Finch et al., 2006 (11) | HR = 0.20 (0.07 to 0.58), N = 1828 | NA | NA | NA | NA | NA |
| Chang-Claude et al., 2007 (14) | NA | NA | NA | HR = 0.56 (0.29 to 1.09), N = 1601 | HR = 0.50 (0.24 to 1.04), N = 1187 | HR = 0.40 (0.07 to 2.44), N = 414 |
| Kauff et al., 2008 (16) | HR = 0.12 (0.03 to 0.41), N = 792 | HR = 0.15 (0.04 to 0.56), N = 498 | HR = 0.00,‡ N = 294 | HR = 0.53 (0.29 to 0.96), N = 597 | HR = 0.61 (0.30 to 1.22), N = 368 | HR = 0.28 (0.08 to 0.92), N = 229 |
*
Hazard ratios (HRs), odds ratios (ORs) (with 95% confidence intervals), and sample size (N) are presented. All P values are two-sided. NA = not applicable.
†
Not included in summary HR estimate because the sample set overlaps with that of other reports. Studies included in the summary estimate were chosen to maximize the sample size (power) of the meta-analysis.
‡
No postsurgery events were observed; 95% CI could not be estimated.